PRODRUG DERIVATIVES OF PROTEIN KINASE C MODULATORS
Embodiments of prodrugs of PKC modulators that show efficacy coupled with low levels of toxicity and improved stability are provided. The prodrug compounds are useful in academic research (animal studies), as candidates for preclinical research, and as therapeutic agents. By taking advantage of a ph...
Saved in:
Main Authors | , , , , |
---|---|
Format | Patent |
Language | English |
Published |
07.01.2021
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Embodiments of prodrugs of PKC modulators that show efficacy coupled with low levels of toxicity and improved stability are provided. The prodrug compounds are useful in academic research (animal studies), as candidates for preclinical research, and as therapeutic agents. By taking advantage of a pharmacophore-based strategy, this design strategy provides access to prodrugs of PKC modulators of diverse scaffolds including tigliane diterpenes, ingenane diterpenes, daphnane diterpene orthoesters, diacylglycerols, and bryostatins, and analogs thereof. In particular, embodiments of the prodrug ingenane esters having substitutions at C20 and their use as therapeutic agents are provided. |
---|---|
Bibliography: | Application Number: US201816604665 |